Clinical-trial start-up is fragmented, and Cori's funding announcement says substantial protocol amendments carry direct costs of around $141,000 for a Phase II protocol and $535,000 for Phase III while also extending recruitment and study duration. The $4 million seed is intended to expand delivery, product and regulatory intelligence as Cori builds on early traction with two of the top five enterprise CROs and Erasmus MC, while the company estimates its approach could cut average trial set-up costs by at least 33%.